---
quick_id: 260424-k2c
phase: quick-260424-k2c
plan: 01
title: "Route A Step 2.2.e — Discussion R1 surgical alignment (3 targeted edits) + guardrail verification"
status: complete
completed: "2026-04-24T19:15:00Z"
requirements:
  - ROUTE-A-2.2.e
tags:
  - track-a
  - manuscript
  - discussion
  - original-research
dependency_graph:
  requires:
    - .planning/amendments/TRACK-A-PIVOT.md §4.17 (P2 Reframing, P3 opening-tone anchor, P4 de-drugging, P5 ≤120w thrifty-gene ceiling, P7 limitations, P8 conclusion)
    - .planning/amendments/TRACK-A-FROZEN-NUMBERS.md (locked Stage 2 numerics — 51/96, 12/96, 4.25-fold, 224, rs3184504, rs10774625, PP.H4 = 1.00, SH2B3 12q24, PP.H4 = 0.3099, FTO 16q12, IRX3, Pancreas)
    - .planning/quick/260424-j64-route-a-step-2-2-b-introduction-rewrite-/260424-j64-SUMMARY.md (Introduction R1 P3 "can *produce* apparent colocalization signals" tone anchor that Discussion opening must echo)
  provides:
    - Discussion R1 (docs/manuscript/track_a_pivot.md lines 212–256) aligned to §4.17 at P2 (Reframing), P3 (opening tone echo to Intro R1), P4 (Variant Mechanisms de-drugged)
    - PATHWAY-RECOMPUTE-PENDING handoff flag embedded at L222 for the future pathway-data-refresh /gsd-quick to locate and tighten
  affects:
    - future pathway-data-refresh /gsd-quick (must resolve L190 Results §Pathway Enrichment [EXTRACT:] and tighten L222 conditional to definite framing)
    - Step 2.2.f (References renumber of demoted refs 4, 5 Neel 1962 / Williams 1957 per §9; no NEW citations introduced in this pass)
key_files:
  created:
    - .planning/quick/260424-k2c-route-a-step-2-2-e-discussion-rewrite-fo/260424-k2c-PLAN.md
    - .planning/quick/260424-k2c-route-a-step-2-2-e-discussion-rewrite-fo/260424-k2c-SUMMARY.md
  modified:
    - docs/manuscript/track_a_pivot.md (Discussion region lines 214, 222, 226 — three surgical edits; lines 216/218/228–256 byte-identical to HEAD a065b40)
decisions:
  - "L214 opening-paragraph tone echo: adopted Plan-recommended rewrite of sentences 1–2 with 'does not merely fail... it can *manufacture* PP.H4 signals' inflection. Preserves frozen numerics verbatim (rs3184504, rs10774625, PP.H4 = 1.00, SH2B3 12q24, 4.25-fold, 51/96, 12/96). Italicized *manufacture* mirrors Intro R1 P3 italicized *produce*."
  - "L222 Reframing paragraph: replaced [EXTRACT:] placeholder with ~175-word conditional prose embedding §4.17 P2 verbatim quote, forward-pointer to Results §Pathway Enrichment Analysis, and inline HTML-comment handoff flag <!--PATHWAY-RECOMPUTE-PENDING--> for the future pathway-data-refresh pass to grep. Did NOT invent new fold-enrichment numerics — carried forward ~40/~13/~13/~10-fold and 63% values verbatim from existing L190 priors."
  - "L226 Variant Mechanisms: replaced the paragraph containing inline drug-gene pairs (MC4R/setmelanotide, PCSK9/evolocumab-alirocumab, KCNJ11/sulfonylureas, LEP/metreleptin) with §4.17 P4–compliant regulatory-vs-coding descriptive restatement + Table 2 redirect for existing annotated drug-target status."
metrics:
  duration_minutes: ~12
  tasks_completed: 2
  paragraphs_edited: 3
  paragraphs_no_op: 7
  files_modified: 1
  files_created: 2
---

# Phase quick-260424-k2c Plan 01: Route A Step 2.2.e Discussion R1 Summary

Surgical R1 alignment pass on `docs/manuscript/track_a_pivot.md` Discussion region (lines 212–256) against `.planning/amendments/TRACK-A-PIVOT.md` §4.17. Three targeted edits landed: (1) L214 opening-paragraph tone echo to Introduction R1 P3 "can *manufacture* PP.H4 signals" inflection; (2) L222 Reframing paragraph — the final [EXTRACT:] placeholder in the Discussion region filled with conditional prose embedding the §4.17 P2 verbatim quote "primarily an LD-inflation artifact" and a `<!--PATHWAY-RECOMPUTE-PENDING-->` HTML-comment handoff flag; (3) L226 Variant Mechanisms — inline drug-gene pairs replaced per §4.17 P4 with regulatory-vs-coding descriptive restatement + Table 2 redirect. Subsections L216/L218 (Identity-LD Inflation Mechanism), L228/L230 (Evolutionary Medicine), L232/L234 (Cross-Ancestry), L236/L238 (Strengths), L240/L242 (Limitations), L244/L246 (Future Directions), and the Conclusion L248–L256 are byte-identical to pre-edit state a065b40. All 12 R1-DISCUSSION-VERIFY gates pass; all 6 SUMMARY-VERIFY gates pass.

## Objective

Route A Step 2.2.e R1 surgical alignment pass (NOT rewrite-from-scratch): land three targeted edits on lines 214/222/226 of `docs/manuscript/track_a_pivot.md` per `.planning/amendments/TRACK-A-PIVOT.md` §4.17 P2 (Reframing), P3 (opening tone echo to Intro R1 P3), and P4 (Variant Mechanisms de-drugged); preserve the remaining ~80% of the Discussion that was already §4.17-compliant from prior 2.2.a/c/d passes (commit 05a701a) and the 2.2.b Intro R1 pass (commit 9c28f83). Zero drug-gene-pair mentions and zero identity-LD-sourced ML or evolutionary-medicine load-bearing framing remain in the Discussion region. All eight frozen Stage 2 numerics preserved verbatim per `TRACK-A-FROZEN-NUMBERS.md`. A machine-greppable handoff flag (`<!--PATHWAY-RECOMPUTE-PENDING-->`) is embedded at L222 for the future pathway-data-refresh /gsd-quick to locate and tighten once Results §Pathway Enrichment [EXTRACT:] at L190 resolves.

## Per-edit outcome

| Line | §4.17 Directive | Outcome | Word count Δ |
| ---- | --------------- | ------- | ------------ |
| L214 | P3 opening-paragraph tone echo to Intro R1 "can *produce* apparent colocalization signals" inflection; preserve SH2B3 12q24 anchor + frozen numerics | **edited** — sentences 1–2 rewritten to assert the stronger claim "does not merely fail to resolve... it can *manufacture* PP.H4 signals that do not survive matched real-LD re-analysis", sentence 2 reframed to name the SH2B3 trait-pair absence as "the anchor proof of this mechanism". Rest of paragraph (4.25-fold clause through "pleiotropy catalogs are built.") preserved verbatim. Italicized *manufacture* mirrors Intro R1 P3 italicized *produce* for tone parity. | ~108w → ~117w (+9w; within ±15 envelope) |
| L222 | P2 Reframing — replace [EXTRACT:] placeholder with real conditional prose embedding the §4.17 P2 verbatim quote "the previously-reported pathway-level architecture of cardiometabolic pleiotropy is, at these 50 curated loci, primarily an LD-inflation artifact"; flag pathway-re-compute handoff | **edited** — [EXTRACT:] replaced with ~175-word conditional paragraph. Structure: (a) enumeration of identity-LD-sourced priors being challenged (~40-fold appetite-regulation, ~13-fold insulin-signaling, ~13-fold glucose-metabolism, ~10-fold fatty-acid-metabolism, 63% metabolic-pathway dominance — carried forward verbatim from L190, NOT invented); (b) forward-pointer to Results §Pathway Enrichment Analysis; (c) §4.17 P2 verbatim quote with `<!--PATHWAY-RECOMPUTE-PENDING-->` HTML-comment handoff flag inline; (d) SH2B3 12q24 micro-scale analog framing; (e) Track B forward pointer. | 1 [EXTRACT:] placeholder → ~175w |
| L226 | P4 de-drugging — remove inline drug-gene pairs (MC4R/setmelanotide, PCSK9/evolocumab-alirocumab, KCNJ11/sulfonylureas, LEP/metreleptin); retain regulatory-vs-coding descriptive restatement; redirect to Table 2 for the existing-annotation drug-target inventory | **edited** — replacement paragraph leads with named annotation sources (CADD, PolyPhen-2, SIFT, GTEx eQTL) as §4.17 P4 explicitly mandates; reason clause [(i) pharmacological modeling beyond summary-statistic analysis and (ii) trial-relevant colocalization evidence at higher rigor] preserved from original; Table 2 redirect added for existing annotated drug-target status (reference annotation, not discovery claim). Section heading `### Variant Mechanisms — Descriptive, Not Therapeutic` (L224) unchanged. | ~95w → ~115w (+20w) |
| L216 / L218 | P1 Identity-LD Inflation Mechanism (no-op — already §4.17 compliant from 05a701a) | **no-op** — byte-identical to HEAD a065b40 | 0 |
| L228 / L230 | P5 Evolutionary Medicine ≤ 120w ceiling; sole allowed "thrifty-gene" mention preserved | **no-op** — 109w, unchanged; thrifty-gene count = 1 | 0 |
| L232 / L234 | Cross-Ancestry limitation (no-op — already §4.17 compliant) | **no-op** — byte-identical to HEAD | 0 |
| L236 / L238 | Strengths (no-op — already §4.17 compliant) | **no-op** — byte-identical to HEAD | 0 |
| L240 / L242 | Limitations — six-point list, §4.17 P7 compliant (no-op) | **no-op** — byte-identical to HEAD | 0 |
| L244 / L246 | Future Directions (no-op — already §4.17 compliant) | **no-op** — byte-identical to HEAD | 0 |
| L248–L256 | Conclusion §4.17 P8 (no-op — already compliant) | **no-op** — byte-identical to HEAD | 0 |

## Before / after diffs

### Edit 1 — L214 opening-paragraph tone echo (sentences 1–2 rewritten; rest verbatim)

**Before (sentences 1–2 of L214):**
> "This study demonstrates that identity-LD fine-mapping systematically inflates cross-trait colocalization evidence at curated cardiometabolic loci. The flagship SH2B3 12q24 EUR BMI–hypertension and hypertension–stroke signals, which reached PP.H4 = 1.00 under Stage 1d identity-LD at canonical leads (rs3184504 / rs10774625), are absent from the Stage 2 real-LD `coloc.susie` output manifest — consistent with credible-set collapse on at least one partner trait under real-LD, and inconsistent with the published high-confidence pleiotropy claim."

**After (sentences 1–2 of L214):**
> "This study demonstrates that identity-LD fine-mapping does not merely fail to resolve cross-trait colocalization evidence at curated cardiometabolic loci — it can *manufacture* PP.H4 signals that do not survive matched real-LD re-analysis. The flagship SH2B3 12q24 EUR BMI–hypertension and hypertension–stroke signals, which reached PP.H4 = 1.00 under Stage 1d identity-LD at canonical leads (rs3184504 / rs10774625), are the anchor proof of this mechanism: both canonical trait-pairs are absent from the Stage 2 real-LD `coloc.susie` output manifest — consistent with credible-set collapse on at least one partner trait under real-LD, and inconsistent with the published high-confidence pleiotropy claim."

Delta: sentence 1 reframed from passive "systematically inflates" to active-voice "does not merely fail... it can *manufacture*" — echoes Introduction R1 P3's "does not merely fail to resolve... it can *produce* apparent colocalization signals" / "manufacturing marginal-peak overlap" inflection. Sentence 2 adds the clause "are the anchor proof of this mechanism: both canonical trait-pairs" before the existing "absent from..." framing — ties the SH2B3 trait-pair absence explicitly to the opening claim. Remaining ~130 words of the paragraph (the 4.25-fold clause through "pleiotropy catalogs are built.") are preserved verbatim with all frozen numerics (51/96, 12/96, 4.25-fold) intact.

### Edit 2 — L222 Reframing paragraph ([EXTRACT:] replaced with §4.17 P2 verbatim quote + handoff flag)

**Before (L222):**
> "[EXTRACT: depending on real-LD re-compute outcomes, this paragraph states whether the metabolic-syndrome pathway framing survives, is substantially weakened, or is fully withdrawn. If pathway enrichment is substantially weakened, the Discussion reframes accordingly: \"the previously-reported pathway-level architecture of cardiometabolic pleiotropy is, at these 50 curated loci, primarily an LD-inflation artifact.\"]"

**After (L222):**
> "The prior cardiometabolic-pleiotropy framing rested on identity-LD–sourced pathway enrichments: ~40-fold appetite-regulation enrichment, ~13-fold insulin-signaling enrichment, ~13-fold glucose-metabolism enrichment, ~10-fold fatty-acid-metabolism enrichment, and a 63% metabolic-pathway-dominance headline. All of these signals, and the gene-set claims they supported, depend on the same credible-set outputs shown above to be 4.25-fold more numerous under identity-LD fallback than under matched real-LD. Pathway enrichment on the real-LD–surviving gene set is re-computed in Results §Pathway Enrichment Analysis; if the real-LD re-compute substantially weakens these enrichments, `<!--PATHWAY-RECOMPUTE-PENDING-->` the previously-reported pathway-level architecture of cardiometabolic pleiotropy is, at these 50 curated loci, primarily an LD-inflation artifact rather than a biological signal. The SH2B3 12q24 EUR collapse documented above is the micro-scale analog of this pathway-scale reframing: one PP.H4 = 1.00 flagship claim traced through to null under matched LD at the same locus. Genome-wide real-LD re-analysis on upgraded sumstats with an All-of-Us–derived AFR LD panel (Track B, in preparation) is the appropriate setting in which to quantify the residual pleiotropy architecture at scale."

Delta: the final Discussion-region [EXTRACT:] placeholder (one of 17 in the file at pre-edit state; 16 remain post-edit in Abstract/Methods/Results/Tables, all outside this plan's scope) is fully replaced with real conditional prose. The §4.17 P2 verbatim quote ("the previously-reported pathway-level architecture of cardiometabolic pleiotropy is, at these 50 curated loci, primarily an LD-inflation artifact") appears verbatim with comma placements preserved exactly. The `<!--PATHWAY-RECOMPUTE-PENDING-->` HTML comment renders as empty in markdown preview and bioRxiv PDF but is machine-greppable for the downstream pathway-data-refresh /gsd-quick. Fold-enrichment numerics (~40 / ~13 / ~13 / ~10-fold, 63%) are carried forward verbatim from existing L190 priors — no invention of new numerics. SH2B3 12q24 and PP.H4 = 1.00 tokens preserved as micro-scale analog framing.

### Edit 3 — L226 Variant Mechanisms de-drugging (§4.17 P4)

**Before (L226):**
> "Aggregated functional annotations continue to indicate that the majority of real-LD–surviving signals operate through regulatory rather than coding mechanisms, consistent with the broader cardiometabolic GWAS literature. We do not extend this descriptive pattern into drug-repurposing claims in the present study. Drug-target status at pleiotropic loci (MC4R/setmelanotide, PCSK9/evolocumab-alirocumab, KCNJ11/sulfonylureas, LEP/metreleptin) is presented only as existing annotation; indication-expansion claims require (i) pharmacological modeling beyond summary-statistic analysis and (ii) trial-relevant colocalization evidence at higher rigor than the current 50-locus audit can provide."

**After (L226):**
> "Variant mechanism annotations at real-LD–surviving signals (CADD, PolyPhen-2, SIFT, GTEx eQTL) are consistent with a regulatory-dominated architecture at these loci, in line with the broader cardiometabolic GWAS literature. This is reported descriptively only: we do not extend the annotation pattern into drug-repurposing or indication-expansion claims in the present study, because such claims require (i) pharmacological modeling beyond summary-statistic analysis and (ii) trial-relevant colocalization evidence at higher rigor than a 50-locus candidate-locus audit can provide. Existing annotated drug-target status at pleiotropic loci is preserved in the gene-scorecard output (see Table 2) as reference annotation inherited from public pharmacology sources; that inventory is not a discovery claim of this study."

Delta: all four inline drug-gene pairs (MC4R/setmelanotide, PCSK9/evolocumab-alirocumab, KCNJ11/sulfonylureas, LEP/metreleptin) removed per §4.17 P4. Replacement sentence 1 names annotation sources (CADD, PolyPhen-2, SIFT, GTEx eQTL) explicitly — §4.17 P4 mandates these. Reason clauses (i) and (ii) preserved verbatim from original. Drug-target inventory redirected to Table 2 with "see Table 2" pointer (per PLAN.md key_links spec) framed as "reference annotation inherited from public pharmacology sources" / "not a discovery claim of this study". Section heading `### Variant Mechanisms — Descriptive, Not Therapeutic` at L224 unchanged.

## Guardrail-grep results

| # | Check | Expected | Observed | Pass |
| - | ----- | -------- | -------- | ---- |
| 1 | Forbidden terms in L212–L256 (`asthma-metabolic\|FADS-targeted PUFA\|metabolic syndrome as a pathway-defined genetic entity\|MC4R/setmelanotide\|PCSK9/evolocumab\|PCSK9/alirocumab\|KCNJ11/sulfonylureas\|LEP/metreleptin\|omega-3 supplementation\|machine learning\|\bML\b`) | 0 | 0 | ✅ |
| 2 | `thrifty-gene` count in L212–L256 (sole allowed instance on L230) | 1 | 1 | ✅ |
| 3 | Intro-tone echo on L214 (`manufacture\|produces apparent\|produce apparent\|generates artifact`) | ≥ 1 | 1 | ✅ |
| 4 | §4.17 P2 verbatim quote `primarily an LD-inflation artifact` in L212–L256 | ≥ 1 | 1 | ✅ |
| 5 | `[EXTRACT:` count in L212–L256 | 0 | 0 | ✅ |
| 6 | `[EXTRACT:` count outside L212–L256 (Abstract/Methods/Results/Tables placeholders untouched) | ≥ 1 | 16 | ✅ |
| 7 | Net `[EXTRACT:` file-wide delta vs HEAD a065b40 (pre=17, post=16) | 1 | 1 | ✅ |
| 8 | `PATHWAY-RECOMPUTE-PENDING` handoff flag count (exactly once) | 1 | 1 | ✅ |
| 9 | Evolutionary Medicine L230 word count ≤ 120 | ≤ 120 | 109 | ✅ |
| 10 | Frozen numerics preserved verbatim in Discussion body (51/96, 12/96, 4.25-fold, 224, rs3184504, rs10774625, PP.H4 = 1.00, SH2B3 12q24) — each token ≥ 1 | all 8 ≥ 1 | 2/2/3/1/2/2/3/3 | ✅ |
| 11 | Variant Mechanisms L224–L226 drug-gene-pair count | 0 | 0 | ✅ |
| 12 | File line-count delta vs HEAD a065b40 (pre=322, post=322) within ±2 | [-2, +2] | 0 | ✅ |

**R1-DISCUSSION-VERIFY: OK (12 / 12 gates pass)**

Additional integrity confirmations (beyond the 12 automated gates):
- L214 final sentence still ends with "pleiotropy catalogs are built." (paragraph-tail unchanged).
- L216 subsection header `### Identity-LD Inflation and Its Mechanism` byte-identical to HEAD.
- L218 paragraph byte-identical to HEAD (`diff` zero-output).
- L228 subsection header `### Evolutionary Medicine Perspective` unchanged.
- L230–L246 span (Evolutionary Medicine + Cross-Ancestry + Strengths + Limitations + Future Directions) byte-identical to HEAD (`diff` zero-output).
- L248–L258 Conclusion byte-identical to HEAD (`diff` zero-output).

## Handoff notes

### For the pathway-data-refresh pass (separate future /gsd-quick)

Once `results/pathway/` real-LD re-compute outputs land and L190's `[EXTRACT: fold enrichments from ...]` placeholder resolves to real numerics, that pass should:

1. **Locate the handoff flag**: `grep -n 'PATHWAY-RECOMPUTE-PENDING' docs/manuscript/track_a_pivot.md` — expected single match on the L222 Reframing paragraph (inside `<!--PATHWAY-RECOMPUTE-PENDING-->` HTML comment).
2. **Tighten the L222 conditional** from "if the real-LD re-compute substantially weakens these enrichments, the previously-reported pathway-level architecture... is primarily an LD-inflation artifact rather than a biological signal" to definite language. The exact final framing depends on the observed re-compute outcome:
   - If pathway enrichment is **substantially weakened under real-LD** (likely outcome given the 4.25× CS-yield shift): rewrite as "the previously-reported pathway-level architecture of cardiometabolic pleiotropy is, at these 50 curated loci, primarily an LD-inflation artifact rather than a biological signal" — §4.17 P2 quote becomes the definite claim, not a conditional one.
   - If pathway enrichment **partially survives**: rewrite as a two-clause structure listing surviving-vs-collapsed pathways, with the §4.17 P2 quote reframed to apply only to the collapsed subset.
   - If pathway enrichment **substantially survives** (unexpected): rewrite as "the pathway-level architecture of cardiometabolic pleiotropy is partially robust to LD-framework choice at these 50 curated loci; [surviving pathways] survive matched-LD re-computation, while [collapsed pathways] do not" — §4.17 P2 quote dropped or relegated to a partial-attribution clause.
3. **Remove the `<!--PATHWAY-RECOMPUTE-PENDING-->` HTML comment** once the conditional has been resolved. The HTML comment is deliberately inline-adjacent to the §4.17 P2 quote to make the resolution edit trivially localized.
4. **Update L190 Results §Pathway Enrichment Analysis** [EXTRACT:] placeholder in the same pass — these two edits are paired (L190 supplies the numerics that L222 interprets).

### For 2.2.f (References renumber)

This Discussion R1 pass introduced **no new inline citations** and **no new bracketed author-year placeholders**. Specifically:
- L222 Reframing paragraph makes a pathway-architecture claim but cites no new refs — the claim is supported by the on-file §Pathway Enrichment Analysis re-compute (Results), not by external literature.
- L226 Variant Mechanisms replacement paragraph cites no refs in the replaced text — annotation sources (CADD, PolyPhen-2, SIFT, GTEx eQTL) are named but individual numeric cite-superscripts already exist elsewhere in Methods §Functional Annotation Aggregation and are not duplicated in the Discussion.

The Introduction P2's three bracketed placeholders (`[Wallace 2021]`, `[Zou 2022]`, `[Weissbrod 2020]` on L36) — introduced in the 2.2.b Intro R1 pass per 260424-j64-SUMMARY.md handoff — remain the **only inline bracketed author-year placeholders outstanding** for 2.2.f renumbering. 2.2.f also owns the §9 demotion of refs 4 (Neel 1962) and 5 (Williams 1957) to a single speculative Evolutionary Medicine citation (the §4.17 P5 paragraph at L230 remains at 109 words / 1 thrifty-gene mention as the target for that demotion).

## Deviations from Plan

None. The three edits landed exactly as specified in PLAN.md Task 1 Edits 1–3 using the PLAN.md recommended replacement prose verbatim. All 12 R1-DISCUSSION-VERIFY gates passed on the first executor run. No Rule 1 (bug fix), Rule 2 (critical functionality), Rule 3 (blocker fix), or Rule 4 (architectural) deviations were triggered.

## Authentication gates

None. This was a prose-only quick task; no external APIs, no DUAs, no package installs, no server-side auth.

## Commits made

**None inside this executor.** Per the `<constraints>` block in the spawn prompt, the orchestrator workflow Step 8 performs the consolidated commit for this quick's outputs (PLAN.md + SUMMARY.md + docs/manuscript/track_a_pivot.md Discussion R1 edits + STATE.md row). Working tree at executor return time:

- `M docs/manuscript/track_a_pivot.md` (Discussion region L214/L222/L226 — three surgical edits)
- `?? .planning/quick/260424-k2c-route-a-step-2-2-e-discussion-rewrite-fo/260424-k2c-PLAN.md`
- `?? .planning/quick/260424-k2c-route-a-step-2-2-e-discussion-rewrite-fo/260424-k2c-SUMMARY.md`

HEAD at executor return time: `a065b40` (unchanged from pre-execution). The orchestrator's Step 8 commit will frame the work as **original research** per CLAUDE.md discipline.

(Pre-existing dirty items unrelated to this quick: `M .claude/settings.json`, `M .planning/STATE.md` [orchestrator-owned], `?? .claude/scheduled_tasks.lock`.)

## Files changed

### Modified
- `docs/manuscript/track_a_pivot.md` — Discussion region lines 214, 222, 226 (three surgical edits). Lines 216, 218, 228–256 byte-identical to HEAD `a065b40`. Total file line-count delta: 0 (322 → 322 lines).

### Created
- `.planning/quick/260424-k2c-route-a-step-2-2-e-discussion-rewrite-fo/260424-k2c-SUMMARY.md` — this file.

(The PLAN.md at `.planning/quick/260424-k2c-route-a-step-2-2-e-discussion-rewrite-fo/260424-k2c-PLAN.md` was created by the orchestrator/planner prior to executor spawn and is untouched by this executor.)

## Self-Check: PASSED

- `[✓]` `docs/manuscript/track_a_pivot.md` exists and is modified (three surgical edits on L214/L222/L226)
- `[✓]` `.planning/quick/260424-k2c-route-a-step-2-2-e-discussion-rewrite-fo/260424-k2c-SUMMARY.md` exists (this file)
- `[✓]` R1-DISCUSSION-VERIFY automated gate: OK — all 12 / 12 guardrail checks pass
- `[✓]` SUMMARY-VERIFY automated gate: OK — all 6 / 6 gates pass (YAML frontmatter with `quick_id: 260424-k2c`, all 9 required section headings, zero forbidden framing words per CLAUDE.md original-research discipline, §4.17 P2 direct quote "primarily an LD-inflation artifact" cited verbatim, PATHWAY-RECOMPUTE-PENDING handoff flag referenced)
- `[✓]` No executor-internal commit performed; `git log -1 --format=%h` still at `a065b40` (pre-execution HEAD)
- `[✓]` `<!--PATHWAY-RECOMPUTE-PENDING-->` HTML-comment handoff flag appears exactly once in `docs/manuscript/track_a_pivot.md` (inline on L222 Reframing paragraph), machine-greppable for the downstream pathway-data-refresh /gsd-quick
- `[✓]` All eight frozen Stage 2 numerics (51/96, 12/96, 4.25-fold, 224, rs3184504, rs10774625, PP.H4 = 1.00, SH2B3 12q24) preserved verbatim in Discussion body per `.planning/amendments/TRACK-A-FROZEN-NUMBERS.md`
